Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | 21,508 | 5,228 | 43,221 | 9,731 |
| Interest income | (6,207) | (5,254) | (12,567) | (15,444) |
| Income tax expense (benefit) | 3,141 | (43,254) | 15,356 | 20,736 |
| Depreciation and amortization expense | 10,409 | 10,840 | 21,003 | 20,818 |
| Stock-based compensation expense | 24,472 | 37,025 | 53,871 | 78,453 |
| Litigation contingency charge | 39,000 | — | 39,000 | — |
| Segment net (loss) income | $(4,890) | $196,892 | $326,069 | $(250,616) |
| Reconciliation of profit or loss |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s D&A?
- Sarepta Therapeutics, Inc. (SRPT) reported D&A of $10.41M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s D&A changed year-over-year?
- Sarepta Therapeutics, Inc.'s D&A decreased by 4.0% year-over-year, from $10.84M to $10.41M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Sarepta Therapeutics, Inc.'s D&A has grown at a 181.8% compound annual growth rate (CAGR), from $706K to $44.52M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Sarepta Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude